Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Leqembi, Kisunla Labels Revised to Strengthen ARIA Monitoring
Labels have been revised for Alzheimer’s disease therapies Leqembi (lecanemab) and Kisunla (donanemab) following a health ministry order issued on June 5, adding new precautions and MRI monitoring recommendations related to amyloid-related imaging abnormalities (ARIAs). The revisions instruct patients and…
To read the full story
Related Article
- Japan Calls for APOE Testing before Leqembi, Kisunla Treatment
August 18, 2026
REGULATORY
- SCARDA, Thai Vaccine Institute Link Up on KM Biologics’ Dengue Shot
October 7, 2026
- MHLW Opens Applications for Innovation Fund’s Ecosystem Program
October 7, 2026
- Takaichi Puts Health Security on Crisis Management Investment Agenda
October 6, 2026
- Japan Has Limited Drug Pricing Cards to Play on MFN, Should Expand CEA: MOF Official
October 5, 2026
- RMPs to Become Statutory Requirement under PMD Act in May 2027
October 5, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…